BeStock  
Stocks › Biotechnology › ABCL

AbCellera Biologics ABCL

US equityMarket cap rank #2395BiotechnologyAI medical concept stocks
$9.69 −$0.78 (-7.45%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.73 +0.41%
Open$10.14
Prev close$10.47
Day range$9.58 – $10.26
Volume4.25M
Market cap$3.16B
P/E (TTM)–
Dividend yield–

ABCL Stock News

Headlines matching AbCellera Biologics or the ABCL ticker, most recent first.

  • J.P. Morgan Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $17Market news · 29 Sep 2026 · Direct mention
  • JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $25Market news · 28 Sep 2026 · Direct mention
  • Goldman Sachs Initiates AbCellera Biologics(ABCL.US) With Hold Rating, Announces Target Price $13Market news · 24 Sep 2026 · Direct mention
  • Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $30Market news · 2 Sep 2026 · Direct mention
  • Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $12Market news · 7 Aug 2026 · Direct mention
  • Cantor Fitzgerald Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $12 PositiveMarket news · 6 Aug 2026 · Direct mention
  • Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $9 PositiveMarket news · 6 Aug 2026 · Direct mention
  • TD Cowen Maintains AbCellera Biologics(ABCL.US) With Buy RatingMarket news · 6 Aug 2026 · Direct mention
  • BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $15Market news · 18 Aug 2026 · Direct mention
  • BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $15 PositiveMarket news · 12 Aug 2026 · Direct mention
  • Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $30Market news · 12 Aug 2026 · Direct mention
  • JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $25 PositiveMarket news · 11 Aug 2026 · Direct mention
  • Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy RatingMarket news · 10 Aug 2026 · Direct mention
  • Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $12 NegativeMarket news · 31 Jul 2026 · Direct mention
  • JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13Market news · 30 Jul 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on ABCL.

Sign in to join the discussion.

Scroll to Top